Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors

DOI PDF 被引用文献15件
  • Ferry Ossendorp
    From the Department of Immunohematology and Bloodbank, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
  • Erica Mengedé
    From the Department of Immunohematology and Bloodbank, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
  • Marcel Camps
    From the Department of Immunohematology and Bloodbank, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
  • Rian Filius
    From the Department of Immunohematology and Bloodbank, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
  • Cornelis J.M. Melief
    From the Department of Immunohematology and Bloodbank, Leiden University Medical Center, 2300 RC Leiden, The Netherlands

抄録

<jats:p>This study shows that induction of tumor-specific CD4+ T cells by vaccination with a specific viral T helper epitope, contained within a synthetic peptide, results in protective immunity against major histocompatibility complex (MHC) class II negative, virus-induced tumor cells. Protection was also induced against sarcoma induction by acutely transforming retrovirus. In contrast, no protective immunity was induced by vaccination with an unrelated T helper epitope. By cytokine pattern analysis, the induced CD4+ T cells were of the T helper cell 1 type. The peptide-specific CD4+ T cells did not directly recognize the tumor cells, indicating involvement of cross-priming by tumor-associated antigen-presenting cells. The main effector cells responsible for tumor eradication were identified as CD8+ cytotoxic T cells that were found to recognize a recently described immunodominant viral gag-encoded cytotoxic T lymphocyte (CTL) epitope, which is unrelated to the viral env-encoded T helper peptide sequence. Simultaneous vaccination with the tumor-specific T helper and CTL epitopes resulted in strong synergistic protection. These results indicate the crucial role of T helper cells for optimal induction of protective immunity against MHC class II negative tumor cells. Protection is dependent on tumor-specific CTLs in this model system and requires cross-priming of tumor antigens by specialized antigen-presenting cells. Thus, tumor-specific T helper epitopes have to be included in the design of epitope-based vaccines.</jats:p>

収録刊行物

被引用文献 (15)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ